Literature DB >> 15075057

Recent advances in the diagnosis of heart failure.

James O O'Neill1, David O Taylor.   

Abstract

Heart failure has reached epidemic proportions and the prevalence is increasing. The accurate and efficient diagnosis of heart failure remains problematic, as signs and symptoms are neither sensitive nor specific. Recent advances in the diagnosis of this condition include a conceptual change in what constitutes heart failure, a greater understanding of heart failure with preserved systolic function, and an abundance of data supporting the use of neurohormonal assays, particularly brain-type natriuretic peptide. These factors will help facilitate earlier diagnosis and targeted treatment of patients with this malady.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075057     DOI: 10.1007/s11886-004-0025-8

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  36 in total

1.  The pregnancy hormone relaxin is a player in human heart failure.

Authors:  T Dschietzig; C Richter; C Bartsch; M Laule; F P Armbruster; G Baumann; K Stangl
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

2.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure.

Authors:  L W Stevenson; J K Perloff
Journal:  JAMA       Date:  1989-02-10       Impact factor: 56.272

Review 3.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

4.  Brain natriuretic peptide levels do not correlate with acute cellular rejection in De Novo orthotopic heart transplant recipients.

Authors:  James O O'Neill; Andrew T McRae; Richard W Troughton; Kenneth Ng; David O Taylor; Mohammed H Yamani; James B Young; Randall C Starling
Journal:  J Heart Lung Transplant       Date:  2005-04       Impact factor: 10.247

5.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study.

Authors:  R Kazanegra; V Cheng; A Garcia; P Krishnaswamy; N Gardetto; P Clopton; A Maisel
Journal:  J Card Fail       Date:  2001-03       Impact factor: 5.712

6.  Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

Authors:  Fraser D Russell; Deborah Meyers; Andrew J Galbraith; Nick Bett; Istvan Toth; Philip Kearns; Peter Molenaar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-06-05       Impact factor: 4.733

7.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Elevated B-type natriuretic peptide levels after anthracycline administration.

Authors:  T Suzuki; D Hayashi; T Yamazaki; T Mizuno; Y Kanda; I Komuro; M Kurabayashi; K Yamaoki; K Mitani; H Hirai; R Nagai; Y Yazaki
Journal:  Am Heart J       Date:  1998-08       Impact factor: 4.749

9.  The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction- cost-effectiveness in relation to open access echocardiography.

Authors:  Victor Sim; David Hampton; Ceri Phillips; Su-Neng Lo; Sanjeev Vasishta; John Davies; Micheal Penney
Journal:  Fam Pract       Date:  2003-10       Impact factor: 2.267

Review 10.  B-type natriuretic peptides: a diagnostic breakthrough for clinicians.

Authors:  Peter A McCullough; Torbjørn Omland; Alan S Maisel
Journal:  Rev Cardiovasc Med       Date:  2003       Impact factor: 2.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.